ABT vs MDT
Abbott Laboratories and Medtronic, both Healthcare
Abbott Laboratories is the larger company at $154B against $102B. On trailing earnings MDT is the cheaper of the two at a P/E of 21.7 against 27.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year MDT returned -5.3% against -25% for ABT. The RyuScore puts MDT ahead, 62 against 60 out of 100.
| Figure | ABT | MDT |
|---|---|---|
| Last close | $99.59 | $88.48 |
| Market cap | $154B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.8 | 21.7 |
| Dividend yield | 2.4% | 3.2% |
| 1-year return | -25% | -5.3% |
| 5-year return | -14% | -21% |
| RyuScoresector-relative, 1–10 | 60/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Abbott Laboratories
Revenue of $11B in Q1 2026, net income $1.1B. Its largest reported line is Nutritional Products, 41% of the disclosed total.
Medtronic
Revenue of $9.8B in Q1 2027, net income $1.5B. Its largest reported line is Total Other Countries Excluding Ireland, 100% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.